MIR570 (MicroRNA 570)

Nude mouse model experiments using hematoxylin and eosin staining and biochemical indexes demonstrated that tLyp-1-EXO-circRAPGEF5 ASO significantly inhibited LUAD metastasis and did not cause biological damage to vital organs. This study clarified the mechanism of tLyp-1-EXO-circRAPGEF5 ASO in inhibiting LUAD metastasis, indicating that circRAPGEF5 may serve as a new intervention target for LUAD metastasis.

Despite the FDA's approval of therapies like Atezolizumab (anti- PD-L1) and Pembrolizumab (anti-PD-1) for certain TNBC cases, more than half of all TNBC patients, especially those with low PD-L1 levels and in advanced stages, remain unresponsive. Therefore, in combination therapy, sulindac downregulating exosomal PD-L1 leads to increased availability of PD-L1 Ab, which potentially improves the overall efficacy of anti-PD-L1 therapy. In conclusion, our findings provide unique insights into the mechanism of action and efficacy for sulindac as an immunomodulatory agent in combination with anti-PD-L1 therapy for the treatment of TNBC.

Circ_0005927 inhibits the proliferation, colony formation, invasion and EMT of GC cells through the upregulation of FOXO3, facilitated by the sequestration of miR-570-3p. Targeting the circ_0005927/miR-570-3p/FOXO3 axis may offer a promising therapeutic approach for GC.

Furthermore, a gene analysis predicted that the target gene set of microRNAs might affect the regulation of TP53 via the epigenetic regulation of MECP2. Taken together, these 4 extracellular vesicle-associated microRNAs in circulation serve as a promising liquid biomarker to identify angiosarcoma patients and trace disease progression.

After being taken up by TAECs, exosomal miR-5703 promotes angiogenesis, EndMT, and barrier damage by targeting ING4. Hence, miR-5703 is a potential target in the lung cancer microenvironment.

In summary, inhibiting the oncogenic miRNAs and ectopic expression of tumor-suppressive miRNAs can decrease prolactin secretion, reduce tumor invasion and migration, enhance dopamine agonist efficacy, and inhibit prolactinoma development. These findings can serve as a blueprint for future translational studies investigating miR-based therapeutics for prolactinoma.

miR-570 can inhibit Wnt/β-catenin expression. Mesoporous silica nanoparticles carrying ligustrazine can promote miR-570 to inhibit Wnt/β-catenin expression, leading to inhibition of HT029cell metastasis.

Estrogen regulates the EZH2/DNMTs/miR-570-3p/DPP4 signaling pathway to promote PTC progression.

Importantly, molecular studies have indicated that the elevated levels of lncRNAFOXD1-AS1 in PC are facilitated through METTL3 and YTHDF1-dependent mA methylation. In summary, our results underscore the critical functions of lncRNA FOXD1-AS1 in the self-renewal and tumorigenesis of pancreatic cancer CSCs, positioning lncRNA FOXD1-AS1 as a promising therapeutic target for PC.

APJ suppression from a specific microRNA in cancer cell‑derived exosomes induced CAF‑like properties in fibroblasts. Thus, the APJ system in fibroblasts in the tumor microenvironment may be a promising therapeutic target.

We identified a potent microRNA, miR-570 that could bind the 3'untranslated regions of multiple HSP mRNAs and inhibit HSP synthesis. Here, we will introduce the transfection and thermotolerance methods for analysis of miR-570 targeting the HSP chaperone network.

The tumor suppressor circ_ATAD3B prevents cancer progression by regulating the miR-570-3p/MX2 pathway. Circ_ATAD3B may be a candidate for targeted therapy of breast cancer.